Table 1 Baseline population characteristics

Age (years)

40 ± 16

53 ± 12

35 ± 15

<0.001

Male n(%)

48 (53.3%)

10 (41.6%)

38 (57.5%)

0.181

BMI (kg/m²)

27.7 ± 3.3

31.7 ± 1.2

26.3 ± 2.6

<0.001

Dyslipidemia n (%)

32 (35.6%)

22 (91.6%)

10 (15.1%)

<0.001

Hypertension n (%)

41 (45.6%)

23 (95.8%)

18 (27.2%)

<0.001

Diabetes n (%)

10 (11.1%)

10 (41.6%)

0 (0%)

<0.001

Creatinine (mg/dl)

1.0 (0.9-1.2)

1.1(1.0-1.2)

1 (0.9-1.0)

0.004

Nitrotyrosine (μmol/L)

0.31 ± 0.07

0.42 ± 0.03

0.27 ± 0.02

<0.001

CRP (mg/dl)

3.7 (1.8-5.3)

5.3 (3.2-7.2)

2.7 (1.7-4.0)

<0.001

PVCs origin site

RVOT n (%)

68 (75.6%)

20 (83.3%)

48 (72.7%)

0.791

LVOT n (%)

19 (21.1%)

3 (12.5%)

16 (24.2)

0.227

CUSPs n (%)

3 (3.3%)

1 (4.1%)

2 (3.0%)

0.610

Echocardiography

LVTDd (mm)

50.0 ± 5.5

50.1 ± 5.3

50.0 ± 5.5

0.933

LVTSd (mm)

28.7 ± 4.6

30.2 ± 4.3

28.1 ± 4.6

0.058

LVEF (%)

57 ± 5

57 ± 3

57 ± 5

0.982

Medication

ACEi/ARBs n (%)

33 (36.7%)

21 (87.5%)

12 (18.1%)

<0.001

Beta blockers n (%)

16 (17.8%)

13 (54.1%)

3 (4.5%)

<0.001

Lipid-lowering therapy n (%)

29 (32%)

19 (79.1%)

10 (15.1%)

<0.001

Class I AADs n (%)

16 (17.8%)

11 (45.8%)

5 (7.5%)

<0.001

Class III AADs n (%)

3 (3.3%)

2 (8.3%)

1 (1.5%)

0.172

Class IV AADs n (%)

3 (3.3%)

2 (8.3%)

1 (8.3%)

0.172

Follow-up months n (%)

39 (32-45)

35 (24-45)

40 (34-45)

0.356